GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » Capex-to-Operating-Income

Zelira Therapeutics (ASX:ZLD) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Zelira Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Zelira Therapeutics's Capital Expenditure for the six months ended in Dec. 2023 was A$0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-3.29 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Zelira Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Zelira Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelira Therapeutics Capex-to-Operating-Income Chart

Zelira Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zelira Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zelira Therapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Zelira Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zelira Therapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's Capex-to-Operating-Income falls into.



Zelira Therapeutics Capex-to-Operating-Income Calculation

Zelira Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -7.263
=N/A

Zelira Therapeutics's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -3.29
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zelira Therapeutics  (ASX:ZLD) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Zelira Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Zelira Therapeutics (ASX:ZLD) Business Description

Traded in Other Exchanges
Address
101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Zelira Therapeutics (ASX:ZLD) Headlines

No Headlines